{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:34:02Z","timestamp":1772793242786,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.amjcard.2009.05.003","type":"journal-article","created":{"date-parts":[[2009,6,16]],"date-time":"2009-06-16T06:04:21Z","timestamp":1245132261000},"page":"1694-1702","source":"Crossref","is-referenced-by-count":50,"title":["Lipid-Altering Efficacy and Safety of Ezetimibe\/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study)"],"prefix":"10.1016","volume":"103","clinical-trial-number":[{"clinical-trial-number":"nct00409773","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jennifer G.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M.","family":"Grundy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willa A.","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Henrik","family":"Parving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeniyi J.","family":"Adewale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam B.","family":"Polis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2009.05.003_bib1","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.05.003_bib2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2005.11.046","article-title":"Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds","volume":"47","author":"Grundy","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.05.003_bib3","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.05.003_bib4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.05.003_bib5","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.05.003_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diab Care"},{"key":"10.1016\/j.amjcard.2009.05.003_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacl.2008.02.002","article-title":"Effect of ezetimibe\/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analyses","volume":"2","author":"Abate","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjcard.2009.05.003_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.amjcard.2004.09.034","article-title":"Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome","volume":"95","author":"Deedwania","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.05.003_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3132\/dvdr.2006.020","article-title":"Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome","volume":"3","author":"Denke","year":"2006","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.amjcard.2009.05.003_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/met.2006.0033","article-title":"Efficacy and safety of ezetimibe\/simvastatin versus simvastatin monotherapy in hypercholesterolemic patients with metabolic syndrome","volume":"5","author":"Feldman","year":"2007","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.amjcard.2009.05.003_bib11","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1185\/030079904X2321","article-title":"Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome","volume":"20","author":"Simons","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2009.05.003_bib12","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1093\/eurheartj\/ehi482","article-title":"A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study","volume":"26","author":"Stalenhoef","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2009.05.003_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/MOL.0b013e3283189c2b","article-title":"Lipid lowering in the patients with prediabetes\/metabolic syndrome: what is the evidence?","volume":"19","author":"Steiner","year":"2008","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2009.05.003_bib14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2009.05.003_bib15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1463-1326.2004.00450.x","article-title":"Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial","volume":"7","author":"Stender","year":"2005","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.amjcard.2009.05.003_bib16","series-title":"Vytorin (ezetimibe\/simvastatin) [package insert]","year":"2009"},{"key":"10.1016\/j.amjcard.2009.05.003_bib17","series-title":"Lipitor (atorvastatin calcium) tablets [package insert]","year":"2009"},{"key":"10.1016\/j.amjcard.2009.05.003_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.amjcard.2009.05.003_bib19","first-page":"921","article-title":"Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update","volume":"69","author":"Genest","year":"2003","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.amjcard.2009.05.003_bib20","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.05.003_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.05.003_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2009.05.003_bib23","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.amjcard.2008.09.075","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease","volume":"102","author":"Conard","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.05.003_bib24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4065\/81.12.1579","article-title":"Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study","volume":"81","author":"Goldberg","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2009.05.003_bib25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.amjcard.2008.09.076","article-title":"Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease","volume":"102","author":"Leiter","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2009.05.003_bib26","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00125-004-1460-1","article-title":"Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk","volume":"47","author":"Westerbacka","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2009.05.003_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/dmrr.666","article-title":"Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease","volume":"22","author":"Schindhelm","year":"2006","journal-title":"Diab Metab Res Rev"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909010261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909010261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T18:46:26Z","timestamp":1558377986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914909010261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0002914909010261"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2009.05.003","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}